← Back to Search

Alkylating Agent

Zimberelimab for Head and Neck Cancers (PANTHEoN Trial)

Phase 1
Waitlist Available
Led By Michael Gibson, MD, PhD
Research Sponsored by Michael K. Gibson
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 and 2 years
Awards & highlights

PANTHEoN Trial Summary

This trial will test the safety of combining two investigational drugs, zimberelimab and etrumadenant, with chemotherapy and radiation to treat head and neck cancer. The study will also look at how the drugs change the microbiome, immune cells, and scarring caused by radiation.

Eligible Conditions
  • Head and Neck Cancer
  • Throat Cancer
  • Oral Cancers
  • Oral Squamous Cell Carcinoma
  • Squamous Cell Carcinoma
  • Oropharyngeal Cancer
  • Oropharyngeal Carcinoma
  • Laryngeal Cancer
  • Hypopharyngeal Cancer

PANTHEoN Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 and 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Effect on fibrosis of inhibition with concurrent chemoradiation treatment with or without PD1 inhibition and with or without the adenosine 2A receptor (A2AR) and adenosine 2B receptor (A2BR)
Effect on imaging correlates of inhibition with concurrent chemoradiation treatment with or without PD1 inhibition and with or without the adenosine 2A receptor (A2AR) and adenosine 2B receptor (A2BR)
Ovulation Inhibition
+5 more
Secondary outcome measures
2-year overall survival
Median overall survival
Median progression-free survival (PFS)
+2 more

Side effects data

From 2014 Phase 4 trial • 45 Patients • NCT02000531
29%
Nausea
19%
Leukopenia
14%
Anaemia
14%
Neutropenia
14%
Thrombocytopenia
14%
Alanine aminotransferase increased
14%
Vomiting
14%
White blood cell count decreased
10%
Platelet count decreased
10%
Aspartate aminotransferase increased
10%
Neutrophil count decreased
5%
Diarrhea
5%
Musculoskeletal pain
5%
Dizziness
5%
Back pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Erlotinib-Chemotherapy
Chemotherapy-Erlotinib

PANTHEoN Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Concurrent Cisplatin/Radiation Therapy + Zimberelimab + Etrumadenant (Cohort 2)Experimental Treatment4 Interventions
Concurrent weekly cisplatin with radiation + etrumadenant + zimberelimab with adjuvant combined etrumadenant + zimberelimab
Group II: Concurrent Cisplatin/Radiation Therapy + Zimberelimab (Cohort 1)Experimental Treatment3 Interventions
Concurrent weekly cisplatin with radiation and zimberelimab therapy followed by adjuvant zimberelimab
Group III: Concurrent Cisplatin/Radiation TherapyActive Control2 Interventions
Concurrent weekly cisplatin with radiation therapy control arm
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Radiation
2003
Completed Phase 3
~1020
Zimberelimab
2018
Completed Phase 1
~50
Etrumadenant
2018
Completed Phase 1
~130
Cisplatin
2013
Completed Phase 3
~1940

Find a Location

Who is running the clinical trial?

Michael K. GibsonLead Sponsor
1 Previous Clinical Trials
54 Total Patients Enrolled
Jennifer Choe, MD, PhDLead Sponsor
Jennifer ChoeLead Sponsor

Media Library

Cisplatin (Alkylating Agent) Clinical Trial Eligibility Overview. Trial Name: NCT04892875 — Phase 1
Head and Neck Cancers Research Study Groups: Concurrent Cisplatin/Radiation Therapy + Zimberelimab (Cohort 1), Concurrent Cisplatin/Radiation Therapy + Zimberelimab + Etrumadenant (Cohort 2), Concurrent Cisplatin/Radiation Therapy
Head and Neck Cancers Clinical Trial 2023: Cisplatin Highlights & Side Effects. Trial Name: NCT04892875 — Phase 1
Cisplatin (Alkylating Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04892875 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent has this medical experiment been embraced by participants?

"This research trial is not presently enrolling patients. The study initiated on February 1st 2023 and was last amended on August 9th 2022. If you are searching for other trials, there exist 3083 clinical studies actively seeking recruits with oral squamous cell carcinoma as well as 689 active investigations involving Zimberelimab in search of participants."

Answered by AI

Are enrollees being accepted for this clinical research at present?

"According to clinicaltrials.gov, this particular medical trial has concluded its search for study participants; the initial post was on February 1st 2023 and it closed recruitment as of August 9th 2022. Nevertheless, there are still 3772 other investigations enrolling patients at present."

Answered by AI

What indications are Zimberelimab treatments commonly given for?

"Zimberelimab is a commonly-prescribed medication for individuals with advanced ovarian cancer, but it has also been used to treat testicular cancer that does not respond well to standard treatments and advance directives."

Answered by AI

Has the Federal Drug Administration sanctioned Zimberelimab?

"There is minimal evidence to support the safety and effectiveness of Zimberelimab, consequently awarding it a score of 1."

Answered by AI

What prior research has been conducted into the effects of Zimberelimab?

"Presently, there are 689 active clinical trials which make use of Zimberelimab with 274 in the final phase. Most of these experiments take place inside Shanghai, but 43234 other locations have a presence for this drug as well."

Answered by AI
~0 spots leftby Dec 2025